Abstract: The present invention provides a frequency selective circuit. The frequency selection circuit comprises a voltage-controlled oscillator, a frequency divider, a frequency selective unit and a register group, the voltage-controlled oscillator is used to output a frequency corresponding to the frequency adjustment window; the frequency divider is used to divide the clock frequency output by the voltage-controlled oscillator, and to feed back the resulting low frequency to the frequency selection unit; the frequency selective unit is used to compare a reference frequency with the resulting low frequency output by the frequency divider, and to provide the frequency adjustment window which is configured based on the frequency search window to the voltage-controlled oscillator. The register group is used to output the frequency search window which is provided to the frequency selective unit.

Abstract: A high-speed sampling circuit is disclosed which comprises a sampling module, a latch module, a first control module, a second control module, and a third control module, the sampling module is used to amplify a differential input signal; the latch module is used to latch the differential output signal of the sampling module; the first control module is used to control the sampling module under a first clock signal; the second control module is used to control the latch module under a second clock signal; the third control module is used to control the output of the differential output signal under the second clock signal.

Abstract: A fixed time-delay circuit of a high-speed interface is disclosed. The fixed time-delay circuit comprises: a counter circuit for generating a shift selection signal of any bit; a data selector circuit for receiving first parallel data signals and rearranging the first parallel data signals according to the shift selection signal and a first low-speed clock to obtain second parallel data signals; a clock selector circuit for selecting, according to the shift selection signal, one clock from multiple input clocks having different phases, for outputting, to form a second low-speed clock; and a synchronization circuit for synchronizing the second parallel data signals according to the second low-speed clock. According to the circuit, initialization alignment among multichannel data of the high-speed interface can be achieved.

Abstract: Disclosed are a clock and data recovery circuit, method and apparatus. The circuit comprises a receiving module for receiving an analog signal; a first equalization module connected to the receiving module, the first equalization module comprising a first totalizer and a second totalizer; a first sampling module connected to an output end of the first totalizer, the first sampling module comprising a first edge sampler and a second edge sampler that are connected to the output end of the first totalizer, respectively; a second sampling module connected to an output end of the second totalizer; a data processing module connected to both the first sampling module and the second sampling module; a clock recovery module connected to the data processing module; and an output module connected to the clock recovery module. In the present application, by means of the manner, a phase can be adjusted using a bias voltage, thereby accurately recovering clock information.

Abstract: A fixed time-delay circuit of a high-speed interface is disclosed. The fixed time-delay circuit comprises: a counter circuit for generating a shift selection signal of any bit; a data selector circuit for receiving first parallel data signals and rearranging the first parallel data signals according to the shift selection signal and a first low-speed clock to obtain second parallel data signals; a clock selector circuit for selecting, according to the shift selection signal, one clock from multiple input clocks having different phases, for outputting, to form a second low-speed clock; and a synchronization circuit for synchronizing the second parallel data signals according to the second low-speed clock. According to the circuit, initialization alignment among multichannel data of the high-speed interface can be achieved.

Abstract: An optical signal processing method and a coherent receiver, wherein an in-phase signal XI in a first polarization direction and an in-phase signal YI in a second polarization direction are added up to obtain a signal I; a quadrature signal XQ in the first polarization direction and a quadrature signal YQ in the second polarization direction are added up to obtain a signal Q; and quantization, combination, and digital signal processing are performed on the I and the Q. After summation, two signals need to be quantized. Therefore, a quantity of ADCs is reduced by half. In addition, because power consumption of a summation component is less than that of an ADS, power consumption of optical signal processing can be reduced. In addition, because there is a preset value, the summation may be performed after phase-inversion is performed on one analog signal, thereby avoiding a signal loss caused by the summation.

Abstract: An optical signal processing method and a coherent receiver, wherein an in-phase signal XI in a first polarization direction and an in-phase signal YI in a second polarization direction are added up to obtain a signal I; a quadrature signal XQ in the first polarization direction and a quadrature signal YQ in the second polarization direction are added up to obtain a signal Q; and quantization, combination, and digital signal processing are performed on the I and the Q. After summation, two signals need to be quantized. Therefore, a quantity of ADCs is reduced by half. In addition, because power consumption of a summation component is less than that of an ADS, power consumption of optical signal processing can be reduced. In addition, because there is a preset value, the summation may be performed after phase-inversion is performed on one analog signal, thereby avoiding a signal loss caused by the summation.

Abstract: A pegylated artesunate derivative, a pharmaceutical composition and uses thereof, the pegylated artesunate derivative is represented by the general formula (I): The pegylated artesunate derivative has activity comparable to that of artesunate, increased water solubility and stability, and an extended half-life in vivo.

Abstract: The present invention relates to site-specific PEGylated linear salmon calcitonin analogs, or pharmaceutically acceptable salts thereof, process for their preparation, pharmaceutical compositions comprising them, and their use for the preparation of a medicament for the treatment or prevention of diseases associated with bone metabolism, e.g., osteoporosis.

Abstract: A pegylated artesunate derivative, a pharmaceutical composition and uses thereof, the pegylated artesunate derivative is represented by the general formula (I): The pegylated artesunate derivative has activity comparable to that of artesunate, increased water solubility and stability, and an extended half-life in vivo.

Abstract: Disclosed are PEG-modified Exendin-4 analogs and uses thereof. In particular, disclosed are PEG-modified Exendin-4 analogs as shown in formula (I), i.e., PEG-M-X-(Ex-4), or pharmaceutically acceptable salts thereof, as well as Exendin-4 analogs as shown in formula (II), i.e., [Aap]Exendin-4, wherein the symbols are as defined in the specification. Further disclosed are methods for preparing PEG-modified Exendin-4 analogs, uses of PEG-modified Exendin-4 analogs, compositions comprising the same, as well as use of the Exendin-4 analogs in the preparation of the PEG-modified Exendin-4 analogs. In the PEG-modified Exendin-4 analogs, modification by polyethylene glycol occurs in a site-directed manner in the peptide chains of the Exendin-4 analogs. The PEG-modified Exendin-4 analogs can be used to prevent and/or treat diseases and/or symptoms related to decreased activity of GLP-1 receptors, such as type II diabetes.

Abstract: Disclosed are PEG-modified Exendin-4 analogs and uses thereof. In particular, disclosed are PEG-modified Exendin-4 analogs as shown in formula (I), i.e., PEG-M-X-(Ex-4), or pharmaceutically acceptable salts thereof, as well as Exendin-4 analogs as shown in formula (II), i.e., [Aap]Exendin-4, wherein the symbols are as defined in the specification. Further disclosed are methods for preparing PEG-modified Exendin-4 analogs, uses of PEG-modified Exendin-4 analogs, compositions comprising the same, as well as use of the Exendin-4 analogs in the preparation of the PEG-modified Exendin-4 analogs. In the PEG-modified Exendin-4 analogs, modification by polyethylene glycol occurs in a site-directed manner in the peptide chains of the Exendin-4 analogs. The PEG-modified Exendin-4 analogs can be used to prevent and/or treat diseases and/or symptoms related to decreased activity of GLP-1 receptors, such as type II diabetes.

Abstract: Disclosed are an injectable sustained-release pharmaceutical formulation and a process for preparing the same. In some embodiments, the formulation comprises an active ingredient in a therapeutically effective amount, an amphipathic molecule, an organic acid and/or a salt thereof which is hardly soluble in water, and an oily solvent. The injectable sustained-release pharmaceutical formulation provides a good sustained-release effect for various active ingredients, in particular peptides, proteins, nucleic acids and saccharides.

Abstract: The present invention relates to site-specific PEGylated linear salmon calcitonin analogues, or pharmaceutically acceptable salts thereof, process for their preparation, pharmaceutical compositions comprising them, and their use for the preparation of a medicament for the treatment or prevention of diseases associated with bone metabolism, e.g., osteoporosis.

Abstract: The instant invention relates to some tripeptide derivatives having activity against endothelin a process for preparing them, pharmaceutical composition containing the same and their use in prevention or treatment of some diseases associated with endothelin.

Abstract: The instant invention relates to some tripeptide derivatives having activity against endothelin a process for preparing them, pharmaceutical composition containing the same and their use in prevention or treatment of some diseases associated with endothelin.